Forbion Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 25

- Investments
- 143
- Portfolio
- 22
- Exits
- 70

Forbion General Information
Description
Founded in 2006, Forbion is a venture capital firm based in Naarden, Netherlands. The firm works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people's lives. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, the firm selects investments that will positively affect the health and well-being of patients. The firm also operates a joint venture with BioGeneration Ventures, which manages three separate seed and early-stage funds focused on Benelux and Germany
Contact Information
- Gooimeer 2-35
- 1411 DC Naarden
- Netherlands
Forbion Investments (143)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
NewAmsterdam Pharma | 14-Jan-2021 | Early Stage VC | 00000 | Drug Discovery | Clinical Trials - General | 00000000 00000 |
00000000 000000000 | 19-Nov-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - General | 000000 0000000000 00.0 |
00000 000000000000 | 11-Nov-2020 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - General | 0000 0000000 |
0000000 | 10-Nov-2020 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 000000 0000000000 00.0 |
000000000 | 08-Sep-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - General | 00000 0000000 00 |
000000000000 00000 | 25-Aug-2020 | 0000 00000 | 000.00 | Drug Discovery | Clinical Trials - General | 000000 00000000 |
0000 000000000000 | 10-Aug-2020 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | 0000 0000000 |
00000000 | 03-Jun-2020 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - Phase 3 | 00000-000 000000 00 |
AM-Pharma | 31-Mar-2020 | Later Stage VC | 00000 | Drug Discovery | Clinical Trials - Phase 3 | 00000-000 000000 00 |
Azafaros | 06-Feb-2020 | Early Stage VC | 000.00 | Drug Discovery | Generating Revenue | 000000 00000000 |
Forbion Exits (70)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Inflazome | 21-Sep-2020 | Merger/Acquisition | 00000 |
0000 000000000000 | 17-Sep-2020 | 000 | 00000 |
00000 000000000000 | 09-Sep-2020 | 000000000000000000 | |
000000000 | 13-Feb-2020 | 000000000000000000 | 00.000 |
0000 000000 | 01-Oct-2019 | 000 00 00000000 | |
000000000 00000000 | 01-Sep-2019 | 000000000000000000 | |
000000000 00000000 | 13-May-2019 | 000 | 000.00 |
0000000 000000 | 18-Apr-2019 | 000 | 0000 |
Mitralign | 12-Mar-2019 | Merger/Acquisition | |
Staten Biotechnology | 17-Dec-2018 | Merger/Acquisition | 00000 |
Forbion Fund Performance
Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
---|
This information is available in the PitchBook Platform. To explore Forbion‘s full profile, request access.
Request a free trialForbion Investments by Industry, Year, and Region
Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialForbion Team (33)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Vincent van Houten | Chief Financial Officer & General Partner | 0 | 0 | Naarden, Netherlands | |
Martien van Osch | Co-Founding Partner & Managing Partner | 00 | 0 | 0 | Naarden, Netherlands |
Geert-Jan Mulder MD | Managing Partner and Co-Founding Partner | 00 | 0 | 0 | Naarden, Netherlands |
Sander Slootweg | Co-Founder & Managing Partner | 0 | 0 | 0 | Naarden, Netherlands |
Holger Reithinger Ph.D | General Partner | 00 | 0 | 0 | Munich, Germany |
Forbion Co-Investors (107)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
BioGeneration Ventures | 4 | 0 |
![]() |
![]() |
|
Fountain Healthcare Partners | 0 | 0 | 0 |
![]() |
![]() |
Novartis Venture Fund | 0 | 0 | 0 |
![]() |
![]() |
Novo Holdings | 0 | 0 |
![]() |
![]() |
|
OrbiMed | 0 | 0 | 0 |
![]() |
![]() |